Evidence map›Paper›PMID 20849373›Full record

ReviewAntioxidants & redox signaling2011

Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer's disease.

Sarah J Texel, Mark P Mattson

Abstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Aging and SKN-1-dependent Loss of 20S Proteasome Adaptation to Oxidative Stress in C. elegans.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017
    Article
  12. Vanillic acid attenuates AβScientific reports · 2017
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Sarah J TexelLaboratory of Neurosciences, National Institute of Aging Intramural Research Program, Baltimore, MD 21224, USA.
Mark P Mattson
Johns Hopkins University · US

Funding

Synaptic Plasticity In Aging And Neurodegenerative DisordersZIAAG000317 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK · 2009 to 2018
$8.5M
Neuroprotective And Neurorestorative Signaling Mechanisms in Alzheimer's DiseaseZIAAG000314 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK · 2009 to 2018
$6.7M
Cellular And Molecular Pathogenesis Of Alzheimer's DiseaseZIAAG000312 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK · 2009 to 2018
$6.4M
Apoptosis In Neurodegenerative DisordersZIAAG000313 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK · 2009 to 2018
$6.4M
Hormesis/Adaptive Stress Responses and AgingZIAAG000331 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK · 2009 to 2018
$5.0M
Dietary Modification Of Brain Aging And Neurodegenerative DisordersZIAAG000315 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK · 2009 to 2018
$5.0M
Neuroscience Training ProgramT32EY017203 · NEI · JOHNS HOPKINS UNIVERSITY · PI BERGLES, DWIGHT E · 2005 to 2014
$2.9M
Apoptosis In Neurodegenerative DisordersZ01AG000313 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK P · 2001 to 2008
$2.1M
Impact of Adverse Life Events on NeuroplasticityZIAAG000330 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK · 2009 to 2014
$2.1M
Dietary Modification Of Brain Aging /NeurodegenerativeZ01AG000315 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK P · 2001 to 2008
$2.0M
Neuroprotective &Neurorestorative Signaling MechanismsZ01AG000314 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK P · 2001 to 2008
$1.9M
Synaptic Plasticity In Aging And Neurodegenerative DisordersZ01AG000317 · NIA · NATIONAL INSTITUTE ON AGING · PI MATTSON, MARK P · 2001 to 2008
$1.7M
Intramural NIH HHS Z01 AG000313Intramural NIH HHS Z01 AG000314Intramural NIH HHS Z01 AG000315Intramural NIH HHS Z01 AG000317Intramural NIH HHS Z01 AG000330Intramural NIH HHS Z01 AG000331NEI NIH HHS T32 EY017203
6 · The paper itself

Abstract

As is generally true with other age-related diseases, Alzheimer's disease (AD) involves oxidative damage to cellular components in the affected tissue, in this case the brain. The causes and consequences of oxidative stress in neurons in AD are not fully understood, but considerable evidence points to important roles for accumulation of amyloid β-peptide upstream of oxidative stress and perturbed cellular Ca(2+) homeostasis and energy metabolism downstream of oxidative stress. The identification of mutations in the β-amyloid precursor protein and presenilin-1 as causes of some cases of early onset inherited AD, and the development of cell culture and animal models based on these mutations has greatly enhanced our understanding of the AD process, and has greatly expanded opportunities for preclinical testing of potential therapeutic interventions. In this regard, and of particular interest to us, is the elucidation of adaptive cellular stress response pathways (ACSRP) that can counteract multiple steps in the AD neurodegenerative cascades, thereby limiting oxidative damage and preserving cognitive function. ACSRP can be activated by factors ranging from exercise and dietary energy restriction, to drugs and phytochemicals. In this article we provide an overview of oxidative stress and AD, with a focus on ACSRP and their potential for preventing and treating AD.

Indexed as

Oxidative StressAlzheimer DiseaseAnimalsHumansModels, Biological

Identifiers

PMID20849373
PMCPMC3061199
OpenAlexW2058114990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.